These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3470 related items for PubMed ID: 26188279

  • 1. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 2. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y, Dong L, Bao S, Wang M, Yun Y, Zhu R.
    Biomed Pharmacother; 2016 Dec 10; 84():462-469. PubMed ID: 27685789
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y, Di W, Yang Q, Lu Z, Cai W, Wu J.
    Clin Lab; 2015 Dec 10; 61(8):1043-51. PubMed ID: 26427150
    [Abstract] [Full Text] [Related]

  • 4. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S, Depreeuw J, Coenegrachts L, Hermans E, Lambrechts D, Amant F.
    Gynecol Oncol; 2015 Jul 10; 138(1):165-73. PubMed ID: 25933683
    [Abstract] [Full Text] [Related]

  • 5. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 6. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y, Li H, Yi D, Sun Y, Bai Y, Zhong S, Song Y, Zhao G, Chen Y.
    Mol Pharm; 2018 Nov 05; 15(11):4912-4925. PubMed ID: 30336060
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P, Li C, Zheng Y, Peng Q, Xiao H, Huang Y, Zhu X.
    Drug Des Devel Ther; 2017 Nov 05; 11():1115-1126. PubMed ID: 28435223
    [Abstract] [Full Text] [Related]

  • 8. Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma.
    Hugle M, Fulda S.
    Cancer Lett; 2015 Apr 28; 360(1):1-9. PubMed ID: 25637161
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
    Dai C, Zhang B, Liu X, Ma S, Yang Y, Yao Y, Feng M, Bao X, Li G, Wang J, Guo K, Ma W, Xing B, Lian W, Xiao J, Cai F, Zhang H, Wang R.
    Endocrinology; 2013 Mar 28; 154(3):1247-59. PubMed ID: 23384836
    [Abstract] [Full Text] [Related]

  • 10. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
    Zhu YR, Min H, Fang JF, Zhou F, Deng XW, Zhang YQ.
    Cancer Biol Ther; 2015 Mar 28; 16(4):602-9. PubMed ID: 25869769
    [Abstract] [Full Text] [Related]

  • 11. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
    Schult C, Dahlhaus M, Glass A, Fischer K, Lange S, Freund M, Junghanss C.
    Anticancer Res; 2012 Feb 28; 32(2):463-74. PubMed ID: 22287733
    [Abstract] [Full Text] [Related]

  • 12. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
    Choi EJ, Cho BJ, Lee DJ, Hwang YH, Chun SH, Kim HH, Kim IA.
    BMC Cancer; 2014 Jan 13; 14():17. PubMed ID: 24418474
    [Abstract] [Full Text] [Related]

  • 13. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
    Yu Z, Zhao G, Xie G, Zhao L, Chen Y, Yu H, Zhang Z, Li C, Li Y.
    Oncotarget; 2015 Oct 20; 6(32):32930-43. PubMed ID: 26431379
    [Abstract] [Full Text] [Related]

  • 14. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
    Zhu Y, Tian T, Zou J, Wang Q, Li Z, Li Y, Liu X, Dong B, Li N, Gao J, Shen L.
    BMC Cancer; 2015 Nov 11; 15():894. PubMed ID: 26560145
    [Abstract] [Full Text] [Related]

  • 15. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
    Brünner-Kubath C, Shabbir W, Saferding V, Wagner R, Singer CF, Valent P, Berger W, Marian B, Zielinski CC, Grusch M, Grunt TW.
    Breast Cancer Res Treat; 2011 Sep 11; 129(2):387-400. PubMed ID: 21046231
    [Abstract] [Full Text] [Related]

  • 16. NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro.
    Wang WJ, Long LM, Yang N, Zhang QQ, Ji WJ, Zhao JH, Qin ZH, Wang Z, Chen G, Liang ZQ.
    Acta Pharmacol Sin; 2013 May 11; 34(5):681-90. PubMed ID: 23603977
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H, Jin X, Zhang Z, Xing Y, Kong X.
    Cell Biochem Funct; 2013 Jul 11; 31(5):427-33. PubMed ID: 23086777
    [Abstract] [Full Text] [Related]

  • 18. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A, Villedieu M, Pétigny-Lechartier C, Brotin E, Louis MH, Abeilard E, Giffard F, Guercio M, Briand M, Gauduchon P, Lheureux S, Poulain L.
    Cancer Lett; 2014 Jun 28; 348(1-2):38-49. PubMed ID: 24650799
    [Abstract] [Full Text] [Related]

  • 19. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines.
    Masuda M, Shimomura M, Kobayashi K, Kojima S, Nakatsura T.
    Oncol Rep; 2011 Nov 28; 26(5):1273-9. PubMed ID: 21725613
    [Abstract] [Full Text] [Related]

  • 20. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Kim A, Park S, Lee JE, Jang WS, Lee SJ, Kang HJ, Lee SS.
    Leuk Res; 2012 Jul 28; 36(7):912-20. PubMed ID: 22560334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 174.